|
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This review summarizes the preclinical and clinical evidence for the potential of PARP inhibitors in genetic breast and ovarian cancers.
|
18837894 |
2008 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP inhibitors target homologous recombination (HR)-deficient tumors, such as the BRCA-associated breast and ovarian cancers.
|
22987487 |
2012 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP inhibition may be a useful therapeutic strategy for a wider range of ovarian cancers bearing deficiencies in the homologous recombination pathway other than just BRCA1/2 mutations.
|
23729402 |
2013 |
|
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.
|
23847380 |
2013 |
|
Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.
|
24168967 |
2013 |
|
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The discovery of the BRCA mutation and its role in ovarian cancer and the clinical application of the concept of synthetic lethality have been the rationale for the successful testing of PARP inhibitors in BRCA mutated ovarian cancer patients.
|
24727989 |
2014 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP inhibition and synthetic lethality in ovarian cancer.
|
24984781 |
2014 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Detecting mutation in BRCA1/2 is a generally accepted strategy for screening ovarian cancers that have impaired homologous recombination (HR) ability and improved sensitivity to PARP inhibitor.
|
25437005 |
2014 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
These studies have prompted the use of PARP inhibitors to treat BRCA1 and BRCA2-deficient ovarian cancers.
|
25490527 |
2015 |
|
Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To define the relative contribution of PARP inhibition to the observed clinical activity, we conducted a randomized phase II trial to determine the response rate of veliparib in combination with cyclophosphamide compared with cyclophosphamide alone in patients with pretreated BRCA-mutant ovarian cancer or in patients with pretreated primary peritoneal, fallopian tube, or high-grade serous ovarian cancers (HGSOC).
|
25589624 |
2015 |
|
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The FDA approval of the PARP inhibitor olaparib for fourth-line therapy of germline BRCA1/2-mutated ovarian cancer represents the first registered indication for this class of drugs in any disease.
|
26169965 |
2015 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gasparri et al discussed new frontiers in therapeutic targets in ovarian cancer with spotlight on PARP inhibitors.
|
26520390 |
2015 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
BRCA mutated ovarian cancers respond better to platinum-based therapy and to the recently approved PARP-inhibitors.
|
26745875 |
2016 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer.
|
26774475 |
2016 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, our data suggested that combined inhibition of PI3K and PARP may be an effective therapeutic strategy for ovarian cancers with PIK3CA mutations and that the accompanied BRCA downregulation following PI3K inhibition could serve as a biomarker for the effective response to PARP inhibition.
|
26909613 |
2016 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer.
|
27016230 |
2016 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several different PARP inhibitors are being trialled in ovarian cancer and this class of drugs has been shown to be a new selective therapy for high-grade ovarian cancer.
|
27065456 |
2016 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting of these pathways, especially through PARP inhibition, is now being exploited therapeutically to effect significant clinical responses in subsets of individuals, particularly in patients with ovarian cancer or prostate cancer, including cancers with a marked metastatic burden.
|
27169997 |
2016 |
|
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRCA mutated ovarian cancers show increased responsiveness to PARP inhibitors.
|
27282964 |
2016 |
|
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The DNA-PK inhibitor, NU7441, induced resistance to rucaparib (<i>P</i> = 0.014) and HR function recovery in a BRCA1-defective cell line.<b>Conclusions:</b> This study has shown that NHEJ is defective in 40% of ovarian cancers, which is independent of HR function and associated with resistance to PARP inhibitors in <i>ex vivo</i> primary cultures.<i></i>.
|
27702817 |
2017 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Results from a phase III trial indicate that maintenance therapy with the PARP inhibitor niraparib is more effective than placebo in slowing the progression of recurrent platinum-sensitive ovarian cancer.
|
27810860 |
2016 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PARP inhibitor Olaparib [AZD2281] has been approved by the FDA for use in pretreated ovarian cancer patients with defective BRCA1/2 genes, and by the EMEA for maintenance therapy in platinum sensitive ovarian cancer patients with defective BRCA1/2 genes.
|
27884198 |
2016 |
|
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The PARP inhibitor olaparib was recently granted Food and Drug Administration (FDA) accelerated approval in patients with advanced BRCA1/2 mutation ovarian cancer.
|
28454085 |
2017 |
|
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Olaparib was the first PARP inhibitor approved by the FDA for patients with BRCA-mutated ovarian cancer.
|
28601509 |
2017 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Originally presumed to inhibit DNA repair, PARP inhibitors that have recently been approved by the FDA for the treatment of advanced ovarian cancer also act as DNA damaging agents by inducing PARP-DNA complexes.
|
28643177 |
2017 |